{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T13:15:09Z","timestamp":1765286109072,"version":"3.46.0"},"reference-count":36,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The aim of this study was to understand profiles of topical Voltaren gel diclofenac (VGD) 2.32 and 1.16% consumers through analyzing prescription patterns and to characterize treatment satisfaction, functional impairment, and pain relief after over-the-counter (OTC) VGD use in Sweden under real-world conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This observational, real-world study conducted in Sweden had retrospective and prospective segments. The retrospective secondary data segment utilized 12-month diclofenac gel prescription data from the Swedish eHealth Agency (E-h\u00e4lsomyndigheten). The prospective segment included electronic surveys completed at baseline and weeks 4 and 12 by adult consumers who purchased OTC VGD to treat their pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Secondary data analyses (\n                      <jats:italic>n<\/jats:italic>\n                      = 12,145) showed that 56.7% of patients receiving diclofenac gel were females \u226570 years old. Most patients did not switch pain treatments; the mean time between diclofenac gel refills was about 2.5 months. From the surveys (\n                      <jats:italic>n<\/jats:italic>\n                      = 264), VGD provided pain relief, indicated by improvement in 11-point pain numeric rating scale scores. Average pain severity at baseline was 5.8 \u2013 improving by a mean of 1.3 and 1.9 points at weeks 4 and 12, respectively. The majority of consumers reported improvement in daily functioning (i.e., health-related quality of life [HRQoL]), and most were at least somewhat satisfied with VGD treatment results.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This real-world study provides important insights into the prescription patterns of diclofenac gel and the consumer experience with OTC VGD in Sweden. Patients rarely switched to other topical nonsteroidal anti-inflammatory drugs, and VGD consumers reported pain relief and improved HRQoL compared to baseline \u2013 resulting in treatment satisfaction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/sjpain-2023-0147","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T05:51:33Z","timestamp":1724133093000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-world evidence evaluation on consumer experience and prescription journey of diclofenac gel in Sweden"],"prefix":"10.1515","volume":"24","author":[{"given":"Deepika","family":"Nair","sequence":"first","affiliation":[{"name":"Medical & Scientific Affairs, Haleon , G\u00e4vlegatan 16, 11330 , Stockholm , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan-Rickard","family":"Norrefalk","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences , Karolinska Institute , Stockholm , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emese","family":"Csoke","sequence":"additional","affiliation":[{"name":"Medical Affairs, GSK Consumer Healthcare , Basel , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa K.","family":"Wilcox","sequence":"additional","affiliation":[{"name":"Evidera , part of Thermo Fisher Scientific , Bethesda , Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilbert","family":"Shanga","sequence":"additional","affiliation":[{"name":"Biostatistics , Haleon , New Jersey , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"key":"2025120910063065621_j_sjpain-2023-0147_ref_001","doi-asserted-by":"crossref","unstructured":"Smith E, Hoy DG, Cross M, Vos T, Naghavi M, Buchbinder R, et al. The global burden of other musculoskeletal disorders: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014;73:1462\u20139.","DOI":"10.1136\/annrheumdis-2013-204680"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_002","doi-asserted-by":"crossref","unstructured":"Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287\u2013333.","DOI":"10.1016\/j.ejpain.2005.06.009"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_003","unstructured":"European Pain Federation. Pain Proposal. Improving the Current and Future Management of Persistent pain, a European Consensus Report; 2010. www.efic.org\/index.asp? sub = B57HFCF6J4043I."},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_004","unstructured":"Bergman S, Herrstrom P, Hogstrom K, Petersson IF, Svensson B, Jacobsson LT. Chronic musculoskeletal pain, prevalence rates, and sociodemographic associations in a Swedish population study. J Rheumatol. 2001;28:1369\u201377."},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_005","doi-asserted-by":"crossref","unstructured":"Brattberg G, Thorslund M, Wikman A. The prevalence of pain in a general population. The results of a postal survey in a county of Sweden. Pain. 1989;37:215\u201322.","DOI":"10.1016\/0304-3959(89)90133-4"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_006","unstructured":"Statensberedning f\u00f6r Medicinsk Utv\u00e4rdering. Methods of treating chronic pain. A systematic review. Stockholm, Sweden: Statensberedning f\u00f6r Medicinsk Utv\u00e4rdering; 2006."},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_007","doi-asserted-by":"crossref","unstructured":"Buchman AS, Shah RC, Leurgans SE, Boyle PA, Wilson RS, Bennett DA. Musculoskeletal pain and incident disability in community-dwelling older adults. Arthritis Care Res (Hoboken). 2010;62:1287\u201393.","DOI":"10.1002\/acr.20200"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_008","doi-asserted-by":"crossref","unstructured":"Schnitzer TJ. Update on guidelines for the treatment of chronic musculoskeletal pain. Clin Rheumatol. 2006;25(Suppl 1):S22\u20139.","DOI":"10.1007\/s10067-006-0203-8"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_009","doi-asserted-by":"crossref","unstructured":"Pergolizzi J, Boger RH, Budd K, Dahan A, Erdine S, Hans G, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8:287\u2013313.","DOI":"10.1111\/j.1533-2500.2008.00204.x"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_010","doi-asserted-by":"crossref","unstructured":"Mason L, Moore RA, Edwards JE, Derry S, McQuay HJ. Topical NSAIDs for acute pain: a meta-analysis. BMC Fam Pract. 2004;5:10.","DOI":"10.1186\/1471-2296-5-10"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_011","doi-asserted-by":"crossref","unstructured":"Mason L, Moore RA, Edwards JE, Derry S, McQuay HJ. Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis. BMC Musculoskelet Disord. 2004;5:28.","DOI":"10.1186\/1471-2474-5-28"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_012","doi-asserted-by":"crossref","unstructured":"Schmidt M, S\u00f8rensen HT, Pedersen L. Diclofenac use and cardiovascular risks: series of nationwide cohort studies. BMJ. 2018;362:k3426.","DOI":"10.1136\/bmj.k3426"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_013","doi-asserted-by":"crossref","unstructured":"Derry S, Moore RA, Gaskell H, McIntyre M, Wiffen PJ. Topical NSAIDs for acute musculoskeletal pain in adults. Cochrane Database Syst Rev. 2015;2015:Cd007402.","DOI":"10.1002\/14651858.CD007402.pub3"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_014","doi-asserted-by":"crossref","unstructured":"Nair B, Taylor-Gjevre R. A review of topical diclofenac use in musculoskeletal disease. Pharmaceuticals (Basel). 2010;3:1892\u2013908.","DOI":"10.3390\/ph3061892"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_015","unstructured":"Alfaro RA, Davis DD. Diclofenac. Treasure Island (FL): StatPearls; 2022."},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_016","doi-asserted-by":"crossref","unstructured":"Maih\u00f6fner C, de Haas A, Sethi V, Shanga G, Wilcox TK, Csoke E, et al. Patients\u2019 experience and utilization patterns of diclofenac gel in Germany: a real-world study with a prospective longitudinal survey and a retrospective analysis of pharmacy data. Curr Med Res Opin. 2023;39:1649\u201361.","DOI":"10.1080\/03007995.2023.2243804"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_017","doi-asserted-by":"crossref","unstructured":"Jensen MP, Turner JA, Romano JM, Fisher LD. Comparative reliability and validity of chronic pain intensity measures. Pain. 1999;83:157\u201362.","DOI":"10.1016\/S0304-3959(99)00101-3"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_018","doi-asserted-by":"crossref","unstructured":"Kapstad H, Hanestad BR, Langeland N, Rust\u00f8en T, Stavem K. Cutpoints for mild, moderate and severe pain in patients with osteoarthritis of the hip or knee ready for joint replacement surgery. BMC Musculoskelet Disord. 2008;9:55.","DOI":"10.1186\/1471-2474-9-55"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_019","doi-asserted-by":"crossref","unstructured":"Li KK, Harris K, Hadi S, Chow E. What should be the optimal cut points for mild, moderate, and severe pain? J Palliative Med. 2007;10:1338\u201346.","DOI":"10.1089\/jpm.2007.0087"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_020","doi-asserted-by":"crossref","unstructured":"Boonstra AM, Stewart RE, Koke AJ, Oosterwijk RF, Swaan JL, Schreurs KM, et al. Cut-Off points for mild, moderate, and severe pain on the numeric rating scale for pain in patients with chronic musculoskeletal pain: variability and influence of sex and catastrophizing. Front Psychol. 2016;7:1466.","DOI":"10.3389\/fpsyg.2016.01466"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_021","doi-asserted-by":"crossref","unstructured":"Poquet N, Lin C. The brief pain inventory (BPI). J Physiother. 2016;62:52.","DOI":"10.1016\/j.jphys.2015.07.001"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_022","unstructured":"Tait RC, Pollard CA, Margolis RB, Duckro PN, Krause SJ. The pain disability index: psychometric and validity data. Arch Phys Med Rehabil. 1987;68:438\u201341."},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_023","doi-asserted-by":"crossref","unstructured":"Predel HG, Giannetti B, Pabst H, Schaefer A, Hug AM, Burnett I. Efficacy and safety of diclofenac diethylamine 1.16% gel in acute neck pain: a randomized, double-blind, placebo-controlled study. BMC Musculoskelet Disord. 2013;14:250.","DOI":"10.1186\/1471-2474-14-250"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_024","doi-asserted-by":"crossref","unstructured":"Galer BS, Rowbotham M, Perander J, Devers A, Friedman E. Topical diclofenac patch relieves minor sports injury pain: results of a multicenter controlled clinical trial. J Pain Symptom Manage. 2000;19:287\u201394.","DOI":"10.1016\/S0885-3924(00)00125-1"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_025","doi-asserted-by":"crossref","unstructured":"Sethi V, Van der Laan L, Gupta S, Piros KC. Perspectives of healthcare professionals towards combination use of oral paracetamol and topical non-steroidal inflammatory drugs in managing mild-to-moderate pain for osteoarthritis in a clinical setting: an exploratory study. J Pain Res. 2022;15:2263\u201372.","DOI":"10.2147\/JPR.S373382"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_026","doi-asserted-by":"crossref","unstructured":"Davis JS, Lee HY, Kim J, Advani SM, Peng H-L, Banfield E, et al. Use of non-steroidal anti-inflammatory drugs in US adults: changes over time and by demographic. Open Heart. 2017;4:e000550.","DOI":"10.1136\/openhrt-2016-000550"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_027","doi-asserted-by":"crossref","unstructured":"Stock SAK, Stollenwerk B, Redaelli M, Civello D, Lauterbach KW. Sex differences in treatment patterns of six chronic diseases: an analysis from the german statutory health insurance. J Women\u2019s Health. 2008;17:343\u201354.","DOI":"10.1089\/jwh.2007.0422"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_028","doi-asserted-by":"crossref","unstructured":"Kim M, Laumbach S, Amico J. Are topical NSAIDs safer than oral NSAIDs when treating musculoskeletal pain? Evidence Based Pract. 2021;24:43.","DOI":"10.1097\/EBP.0000000000000833"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_029","doi-asserted-by":"crossref","unstructured":"Barbosa CD, Balp MM, Kulich K, Germain N, Rofail D. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence. 2012;6:39\u201348.","DOI":"10.2147\/PPA.S24752"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_030","doi-asserted-by":"crossref","unstructured":"Tawil S, Iskandar K, Salameh P. Pain management in hospitals: patients\u2019 satisfaction and related barriers. Pharm Pract (Granada). 2018;16:1268.","DOI":"10.18549\/PharmPract.2018.03.1268"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_031","doi-asserted-by":"crossref","unstructured":"Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain. 2004;8:283\u201391.","DOI":"10.1016\/j.ejpain.2003.09.004"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_032","doi-asserted-by":"crossref","unstructured":"Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105\u201321.","DOI":"10.1016\/j.jpain.2007.09.005"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_033","doi-asserted-by":"crossref","unstructured":"Kendrick DB, Strout TD. The minimum clinically significant difference in patient-assigned numeric scores for pain. Am J Emerg Med. 2005;23:828\u201332.","DOI":"10.1016\/j.ajem.2005.07.009"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_034","doi-asserted-by":"crossref","unstructured":"Takeda O, Chiba D, Ishibashi Y, Tsuda E. Patient-physician differences in desired characteristics of NSAID plasters: An online survey. Pain Res Manag. 2017;2017:5787854.","DOI":"10.1155\/2017\/5787854"},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_035","unstructured":"Dziechciaz M, Balicka-Adamik L, Filip R. The problem of pain in old age. Ann Agric Environ Med. 2013;1:35\u20138."},{"key":"2025120910063065621_j_sjpain-2023-0147_ref_036","doi-asserted-by":"crossref","unstructured":"Bohman H, Ryan J, Stjernborg V, Nilsson D. A study of changes in everyday mobility during the Covid-19 pandemic: As perceived by people living in Malm\u00f6, Sweden. Transp Policy (Oxf). 2021;106:109\u201319.","DOI":"10.1016\/j.tranpol.2021.03.013"}],"container-title":["Scandinavian Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/sjpain-2023-0147\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/sjpain-2023-0147\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T13:08:07Z","timestamp":1765285687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/sjpain-2023-0147\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,3,7]]},"published-print":{"date-parts":[[2024,3,7]]}},"alternative-id":["10.1515\/sjpain-2023-0147"],"URL":"https:\/\/doi.org\/10.1515\/sjpain-2023-0147","relation":{},"ISSN":["1877-8879"],"issn-type":[{"type":"electronic","value":"1877-8879"}],"subject":[],"published":{"date-parts":[[2024,1,1]]},"article-number":"20230147"}}